Trial Profile

To evaluate if Computed tomography textural analysis (CTTA) can predict treatment response in metastatic epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (mNSCLC) with T790M mutations (T790M+) treated with osimertinib

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 26 Mar 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Mar 2019 New trial record
27 Feb 2019 Results presented at the 17th International Congress on Targeted Anticancer Therapies

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com